GSK’s Priorix Receives the US FDA’s Approval for the Prevention of Measles, Mumps and Rubella in Patients Aged ≥12 Months
- The US FDA has approved Priorix for active immunization to treat measles, mumps, and rubella in patients aged ≥12mos.
- Priorix's safety was investigated in 6 clinical trials in 12151 patients (6,391 in the US) who received at least 1 dose of the vaccine. Priorix's efficacy was established using immunogenicity data over comparator vaccine
- Priorix can be administered as a first dose followed by a second one. The vaccine can also be administered as a second dose for individuals who have previously received the first dose of another MMR-containing vaccine. Priorix is currently licensed in 100+ countries globally including all EU countries, Canada, Australia, and New Zealand & has distributed ~800M doses
Ref: GSK | Image: GSK
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.